These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 33518465)

  • 41. Clinical Practices for Measles-Mumps-Rubella Vaccination Among US Pediatric International Travelers.
    Hyle EP; Rao SR; Bangs AC; Gastañaduy P; Fiebelkorn AP; Hagmann SHF; Walker AT; Walensky RP; Ryan ET; LaRocque RC
    JAMA Pediatr; 2020 Feb; 174(2):e194515. PubMed ID: 31816033
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccination Against Measles, Mumps, Rubella and Incident Inflammatory Bowel Disease in a National Cohort of Privately Insured Children.
    Kim C; Yin Z; Kamdar N; Stidham R
    Inflamm Bowel Dis; 2023 Mar; 29(3):430-436. PubMed ID: 35986719
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Economic evaluation on different two-dose-vaccination-strategies related to Measles, Mumps and Rubella Combined Attenuated Live Vaccine].
    He HQ; Zhang B; Yan R; Li Q; Fu J; Tang XW; Zhou Y; Deng X; Xie SY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2016 Aug; 37(8):1121-6. PubMed ID: 27539345
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Long-term immunity to measles, mumps and rubella after MMR vaccination among children with bone marrow transplants.
    Spoulou V; Giannaki M; Vounatsou M; Bakoula C; Grafakos S
    Bone Marrow Transplant; 2004 Jun; 33(12):1187-90. PubMed ID: 15077129
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Two-year antibody persistence in children vaccinated at 12-15 months with a measles-mumps-rubella virus vaccine without human serum albumin.
    Berry AA; Abu-Elyazeed R; Diaz-Perez C; Mufson MA; Harrison CJ; Leonardi M; Twiggs JD; Peltier C; Grogg S; Carbayo A; Shapiro S; Povey M; Baccarini C; Innis BL; Henry O
    Hum Vaccin Immunother; 2017 Jul; 13(7):1516-1522. PubMed ID: 28481690
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Measles, mumps, and rubella--vaccine use and strategies for elimination of measles, rubella, and congenital rubella syndrome and control of mumps: recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Watson JC; Hadler SC; Dykewicz CA; Reef S; Phillips L
    MMWR Recomm Rep; 1998 May; 47(RR-8):1-57. PubMed ID: 9639369
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-term immunoprotection after live attenuated measles-mumps-rubella booster vaccination in children with juvenile idiopathic arthritis.
    Hamad Saied M; van Straalen JW; de Roock S; de Joode-Smink GCJ; Verduyn Lunel FM; Swart JF; Wulffraat NM; Jansen MHA
    Vaccine; 2023 Aug; 41(37):5477-5482. PubMed ID: 37516575
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The safety and immunogenicity of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children: a study of manufacturing consistency and persistence of antibody.
    Lieberman JM; Williams WR; Miller JM; Black S; Shinefield H; Henderson F; Marchant CD; Werzberger A; Halperin S; Hartzel J; Klopfer S; Schödel F; Kuter BJ;
    Pediatr Infect Dis J; 2006 Jul; 25(7):615-22. PubMed ID: 16804432
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new measles mumps rubella (MMR) vaccine: a randomized comparative trial for assessing the reactogenicity and immunogenicity of three consecutive production lots and comparison with a widely used MMR vaccine in measles primed children.
    Lee CY; Tang RB; Huang FY; Tang H; Huang LM; Bock HL
    Int J Infect Dis; 2002 Sep; 6(3):202-9. PubMed ID: 12718836
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Antibody persistence for 3 years following two doses of tetravalent measles-mumps-rubella-varicella vaccine in healthy children.
    Knuf M; Zepp F; Helm K; Maurer H; Prieler A; Kieninger-Baum D; Douha M; Willems P
    Eur J Pediatr; 2012 Mar; 171(3):463-70. PubMed ID: 21935584
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunogenicity and reactogenicity of a single dose of live attenuated varicella vaccine and a booster dose of measles-mumps-rubella vaccine given concomitantly at 12 years of age.
    Parment PA; Svahn A; Rudén U; Bråkenhielm G; Storsaeter J; Akesson L; Linde A
    Scand J Infect Dis; 2003; 35(10):736-42. PubMed ID: 14606613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Mass vaccination programme aimed at eradicating measles, mumps and rubella in Sweden: vaccination of schoolchildren.
    Böttiger M; Christenson B; Taranger J; Bergman M
    Vaccine; 1985 Jun; 3(2):113-6. PubMed ID: 4036269
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Reactogenicity and immunogenicity of a new combined measles-mumps-rubella vaccine: results of a multicentre trial. The Cooperative Group for the Study of MMR vaccines.
    Crovari P; Gabutti G; Giammanco G; Dentico P; Moiraghi AR; Ponzio F; Soncini R
    Vaccine; 2000 Jun; 18(25):2796-803. PubMed ID: 10812221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity and reactogenicity of a new measles, mumps and rubella vaccine when administered as a second dose at 12 y of age.
    Gothefors L; Bergström E; Backman M
    Scand J Infect Dis; 2001; 33(7):545-9. PubMed ID: 11515768
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Antibodies to measles, mumps, and rubella virus in Thai children after two-dose vaccination at 9 months and 2.5 years: A longitudinal study.
    Wanlapakorn N; Puenpa J; Thongmee T; Srimuan D; Thatsanathorn T; Vongpunsawad S; Poovorawan Y
    Vaccine; 2020 May; 38(24):4016-4023. PubMed ID: 32331806
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response to measles-mumps-rubella vaccine in children with autism spectrum disorders.
    Gentile I; Bravaccio C; Bonavolta R; Zappulo E; Scarica S; Riccio MP; Settimi A; Portella G; Pascotto A; Borgia G
    In Vivo; 2013; 27(3):377-82. PubMed ID: 23606694
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunogenicity and reactogenicity of tetravalent vaccine for measles, mumps, rubella and varicella (MMRV) in healthy children: a meta-analysis of randomized controlled trials.
    Leung JH; Hirai HW; Tsoi KK
    Expert Rev Vaccines; 2015; 14(8):1149-57. PubMed ID: 26081133
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The risk of non-specific hospitalised infections following MMR vaccination given with and without inactivated vaccines in the second year of life. Comparative self-controlled case-series study in England.
    Andrews N; Stowe J; Thomas SL; Walker JL; Miller E
    Vaccine; 2019 Aug; 37(36):5211-5217. PubMed ID: 31375437
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Immunogenicity and safety assessments after one and two doses of a refrigerator-stable tetravalent measles-mumps-rubella-varicella vaccine in healthy children during the second year of life.
    Schuster V; Otto W; Maurer L; Tcherepnine P; Pfletschinger U; Kindler K; Soemantri P; Walther U; Macholdt U; Douha M; Pierson P; Willems P
    Pediatr Infect Dis J; 2008 Aug; 27(8):724-30. PubMed ID: 18600190
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Response to measles, mumps, and rubella revaccination in HIV-infected children with immune recovery after highly active antiretroviral therapy.
    Aurpibul L; Puthanakit T; Sirisanthana T; Sirisanthana V
    Clin Infect Dis; 2007 Sep; 45(5):637-42. PubMed ID: 17683001
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.